by WC Gerth 2024 Cited by 46Gerth et al: Losartan and ESRD costs. S-70. Table 2. RENAAL: Within-trial cumulative incidence of ESRD by duration of follow-up. Difference. Follow-up. Losartan.
Among patients with diabetic nephropathy, losartan reduced doubling of serum creatinine and progression to ESRD but provided no mortality benefit.
Among patients with diabetic nephropathy, losartan reduced doubling of serum creatinine and progression to ESRD but provided no mortality benefit.
by DA Sica 2024 Cited by 31(ESRD). Objective: To investigate the pharmacokinetics and pharmacodynamics of losartan in patients with ESRD in order to establish administration guidelines.
Background Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension. This compound is in common use in populations with renal failure and end-stage renal disease (ESRD). Objective To investigate the pharmacokinetics and pharmacodynamics of losartan in patients with ESRD in order to establish administration guidelines. Methods
Patients with CKD and T2DM are at increased risk of ESRD, and cardiovascular morbidity and mortality. Losartan. Eprosartan. Irbesartan. V.
Losartan potassium . subjects with ESRD on haemodialysis. The Cmax of canagliflozin was increased by 13%, 29%, and 29% in subjects with mild, moderate
(ESRD) and death by 20% in comparison with the placebo group and 23 Losartan had no effect on the rate of death or the composite
Losartan significantly reduced the risk for the combined endpoint of end‐stage renal disease (ESRD), MI, stroke, or death by 21% (p 0.005), irrespective of whether all‐cause or cardiovascular death was included in the analysis. In addition, losartan reduced the risk for the composite of ESRD or cardiovascular death by 19.2% (p 0.05).
Comments